Journal
VIRUS RESEARCH
Volume 247, Issue -, Pages 94-101Publisher
ELSEVIER
DOI: 10.1016/j.virusres.2018.02.009
Keywords
Transfected C-33A cells; HPV16 E6; E6 splice donor mutant; E6 spliced forms; Apoptosis resistance; Cisplatin
Categories
Funding
- CONACyT, Mexico [368874]
- CINVESTAV
- CONACyT [128686, 256261]
Ask authors/readers for more resources
The HPV-16 E6/E7 bicistronic immature transcript produces 4 mature RNAs: the unspliced HPV-16 E6/E7(pre-mRNA) product and 3 alternatively spliced mRNAs. The 3 spliced mRNAs encode short forms of the E6 oncoprotein, namely E6*I, E6*II and E6<^>E7. In this study we showed that transfection of C-33A cells with monocistronic constructs of these cDNAs fused to GFP, produced different effects on apoptosis, after the treatment with cisplatin. Transfection of C-33A cells with the full-length E6-GPP oncoprotein resulted in a 50% decrease in cell death, while the transfection with the E6*I-GFP construct showed only a 25% of diminution of cell death, compared to the control cells. Transfection with the E6<^>E7-GFP of E7-GFP construct had no effect on the number of the apoptotic cells, compared with control cells. Conversely, transfection with the E6*II construct resulted in higher cell death than the control cells. Taken together, these results suggested that E6*I or E6*II, the short forms of HPV-16 E6, displayed opposite effects on cisplatin-induced apoptosis, when transfected in C-33A cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available